Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on LIFELINE SCIENTIFIC INC. We currently have 12 research reports from 2 professional analysts.
|08Dec16 16:58||RNS||CLOSING OF THE MERGER - CANCELLATION FROM AIM|
|10Nov16 07:00||RNS||Date of merger closing and cancellation|
|06Oct16 15:18||RNS||RESULTS OF SPECIAL MEETING|
|26Sep16 07:00||RNS||Half-year Report|
|14Sep16 17:13||RNS||Publication of Proxy Statement & Notice of Meeting|
|02Sep16 07:01||RNS||Recommended Cash Acquisition|
|02Sep16 07:00||RNS||Trading update|
Frequency of research reports
Research reports on
LIFELINE SCIENTIFIC INC
LIFELINE SCIENTIFIC INC
A Quarterly look at UK Healthcare
02 Nov 16
Today we publish PG:GP (Panmure Gordon: Growth Prospects), our first quarterly take on the healthcare sector. We see current macro volatility providing a strong backdrop for the more naturally defensive healthcare stocks which are underpinned by solid fundamental drivers. The run-up to the US Presidential election has repeatedly reminded us that pharmaceutical pricing is one of Hilary Clinton’s main targets, and whatever the result, we see a see greater emphasis on outcomes-based pricing and reimbursement as a major influence for the future. In the UK, concerns voiced by the pharma majors over use of new drugs in the UK post Brexit may encourage adoption of some of the recommendations published last week in the UK Government’s final report on the Accelerated Access Review.
Panmure Morning Note 26-09-2016
26 Sep 16
Following the company’s statement on 2 September 2016 (recommended cash acquisition, trading update) the company has issued interim results this morning. Given the ongoing process set in train following the announcement of the definitive merger agreement with Shanghai Genext Medical Technology Co. Ltd (SGM) (02 September 2016) we retain our recommendation and forecasts Under Review.
Panmure Morning Note 02-09-2016
02 Sep 16
This morning Lifeline Scientific has announced it has entered into a definitive merger agreement with Shanghai Genext Medical Technology Co. Ltd (SGM) and, separately, released a trading update for the 6 months ending 30 June 2016. The cash offer from SGM values Lifeline Scientific at circa $87.8m or $4.083 in cash per share. If approved the transaction is expected to close in the fourth quarter calendar 2016 and by no later than 9 December 2016. We remind investors that LSI is incorporated in the State of Delaware in the USA and the merger is proposed in accordance with the Delaware General Corporation Law. The acquisition is not subject to the UK City Code on Takeovers and Mergers and is subject to shareholder approval. We retain our recommendation and forecasts Under Review.
Panmure Morning Note 27-4-2016
27 Apr 16
FY15 headline numbers were highlighted in January’s trading update: revenues $39.4m, operating profit $5.7m (2014: $2.4m). Year-end cash $6.9m – company is now debt free having paid off revolver balance of $2.2m by year-end. Strategic review – company is in discussions with interested parties, which may or may not lead to an offer. Usual caveats on outcomes and timing apply, but given the Board expects to provide a further update by end June, we assume Lifeline is probably quite deep into the process and this looks like the lead in terms of possible strategic options.
Panmure Morning Note 19-01-16
19 Jan 16
Further to Lifeline's ahead-of-expectations trading update and announced stocking order ($3.3m) from its principal distributor in China (18 December 2015), the company has today released further detail on the year ending 31 December 2015. While the strategic and financial review announced on 21 September 2015 is still ongoing, strong operational progress is clearly being delivered and the confident tone of the statement is well-deserved. Prelims are expected by the end of April 2016.
Consistently strong growth at a sensible price
24 Feb 17
In “Alice in Wonderland”, Lewis Carroll tells the story of a girl, who falls through a rabbit hole into a world populated by peculiar, anthropomorphic creatures. Here, Alice crosses swords with the Queen of Hearts, meets the Cheshire Cat and is invited to the "Mad Hatters” tea party, which she subsequently discovers is “stupid”.
Interim results – adhering to international growth strategy
23 Feb 17
Interim results showed a strong performance for Tristel, 6% ahead of its AGM statement on 12 December at which it indicated adjusted pre-tax profits to be no less than £1.6m. Revenues increased by 22% (16% at constant exchange rates – CER or 12% CER excluding the impact of the Australian acquisition) and adjusted pre-tax profits were up 15% to £1.71m. Despite the strong half, we leave our full-year forecasts unchanged, given FX uncertainty and a one-off stocking order in H1 from the NHS, although at current FX rates the risk to our forecasts is considered to be to the upside. However, we raise our target price by 10% to 165p to reflect the solid progress as well as rolling forward our multiples to calendar-adjusted 2017.
£21m equity raise to accelerate growth
22 Feb 17
Blindly following what others do is often a recipe for disaster. However, when an army of ‘super smart’ fund managers snap-up a big holding in a rapidly expanding small-cap that owns ‘disruptive’ technology addressing multi-$billion markets, then it is usually worth taking note. This is exactly what has happened at Kromek, a next generation radiation detection firm. Having just successfully completed its oversubscribed £20m placing and £1m open offer at 20p/share - supported by esteemed investors such as Gervais Williams at Miton (largest shareholder at 19.0%) and Katie Potts (Herald 5.35%), as well as several others such as Schroders (5.0%) and Killik (4.1%).
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
N+1 Singer - Anpario - Feed for growth
24 Feb 17
Anpario’s natural animal feed additive product offering is well placed to benefit from the increasing demand for animal protein and tightening regulations around antibiotic use as growth promoters. The group is in a transition phase, building strong commercial relationships with end users, which we believe should benefit the margin. Anpario’s geographical diversity is a key positive and with a strong balance sheet there is potential for acquisitive as well as organic growth. We initiate coverage with a 354p Target Price and a Buy recommendation ahead of FY results on 8th March.
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals